PSY7-5 Current status and future perspectives in biliary tract cancer in Korea

There are huge unmet medical needs in biliary tract cancer. Biliary cancer is non-rare Asia especially Korea. As a 1st-line chemotherapy, gemcitabine/cisplatin current standard of care, and 2nd-line setting, FOLFOX improved overall survival compared with best supportive care. heterogenous group not only primary origin but also molecular characteristics. Somatic alterations the KRAS, TP53, CDKN2A, SMAD4, BAP1, ARID1A, PBRM1 IDH1/2 have been reported. In recent study, 38.9% cases harbor potentially targetable genetic alteration including FGFR1, FGFR2, FGFR3, PIK3CA, ALK, EGFR, ERBB2, BRAF, AKTS, IDH1, IDH2, CCND1, CCND3, MDM2, BRCA1 BRCA. Targeting those now being tried clinical trials. Among them, targeting FGFR FGFR2 fusion far advanced its development, which followed by mutant IDH1. This era immunotherapy cancers. Anti-PD1 or PDL1 antibody has shown early antitumor efficacy PD1/PDL1 inhibitor other immune targets chemotherapy combination under investigation. Clinical trials new drug development strategy targeted agents immuno-oncologic actively ongoing